Pyxis Oncology (NASDAQ:PYXS) Coverage Initiated by Analysts at Wedbush

Wedbush began coverage on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note issued to investors on Tuesday. The firm set an “outperform” rating and a $6.00 price target on the stock. Wedbush’s target price would suggest a potential upside of 240.91% from the company’s previous close.

A number of other analysts have also recently issued reports on PYXS. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Tuesday, March 24th. Wall Street Zen upgraded Pyxis Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 13th. Stifel Nicolaus decreased their target price on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, March 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $6.83.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $1.76 on Tuesday. Pyxis Oncology has a 12 month low of $0.97 and a 12 month high of $5.55. The company has a 50-day moving average of $1.55 and a 200-day moving average of $2.36. The company has a market cap of $110.58 million, a P/E ratio of -1.36 and a beta of 1.43.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06. The company had revenue of $11.04 million for the quarter, compared to analyst estimates of $0.13 million. As a group, equities research analysts anticipate that Pyxis Oncology will post -1.24 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC boosted its holdings in Pyxis Oncology by 1,939.3% in the 4th quarter. Barclays PLC now owns 60,385 shares of the company’s stock worth $69,000 after acquiring an additional 57,424 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Pyxis Oncology by 37.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock valued at $58,000 after purchasing an additional 13,550 shares in the last quarter. HRT Financial LP raised its position in shares of Pyxis Oncology by 157.5% in the 4th quarter. HRT Financial LP now owns 39,649 shares of the company’s stock valued at $45,000 after purchasing an additional 24,251 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Pyxis Oncology in the 2nd quarter valued at approximately $40,000. Finally, LPL Financial LLC raised its position in shares of Pyxis Oncology by 150.7% in the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock valued at $40,000 after purchasing an additional 21,100 shares in the last quarter. Hedge funds and other institutional investors own 39.07% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.